601 related articles for article (PubMed ID: 24259738)
1. Inaccuracy of point-of-care international normalized ratio in rivaroxaban-treated patients.
Baruch L; Sherman O
Ann Pharmacother; 2013 Sep; 47(9):1210-2. PubMed ID: 24259738
[TBL] [Abstract][Full Text] [Related]
2. Potential inaccuracy of point-of-care INR in dabigatran-treated patients.
Baruch L; Sherman O
Ann Pharmacother; 2011 Jul; 45(7-8):e40. PubMed ID: 21712509
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
4. End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.
Mahaffey KW; Hellkamp AS; Patel MR; Hannan KL; Schwabe K; Nessel CC; Berkowitz SD; Halperin JL; Hankey GJ; Becker RC; Piccini JP; Breithardt G; Hacke W; Singer DE; Califf RM; Fox KA
Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):470-8. PubMed ID: 23759472
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
ROCKET AF Study Investigators
Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
[TBL] [Abstract][Full Text] [Related]
7. A comparison of point-of-care instruments designed for monitoring oral anticoagulation with standard laboratory methods.
Gosselin R; Owings JT; White RH; Hutchinson R; Branch J; Mahackian K; Johnston M; Larkin EC
Thromb Haemost; 2000 May; 83(5):698-703. PubMed ID: 10823265
[TBL] [Abstract][Full Text] [Related]
8. Interpretation of point-of-care INR results in patients treated with dabigatran.
van Ryn J; Baruch L; Clemens A
Am J Med; 2012 Apr; 125(4):417-20. PubMed ID: 22306274
[TBL] [Abstract][Full Text] [Related]
9. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
[TBL] [Abstract][Full Text] [Related]
10. Oral rivaroxaban for symptomatic venous thromboembolism.
; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
[TBL] [Abstract][Full Text] [Related]
11. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
12. Measuring international normalized ratios in long-term care: a comparison of commercial laboratory and point-of-care device results.
Bluestein D; Brantley C; Barnes-Eley M; Gravenstein S; Basta S
J Am Med Dir Assoc; 2007 Jul; 8(6):404-8. PubMed ID: 17619039
[TBL] [Abstract][Full Text] [Related]
13. The clinical significance of differences between point-of-care and laboratory INR methods in over-anticoagulated patients.
Lawrie AS; Hills J; Longair I; Green L; Gardiner C; Machin SJ; Cohen H
Thromb Res; 2012 Jul; 130(1):110-4. PubMed ID: 21937093
[TBL] [Abstract][Full Text] [Related]
14. International normalized ratio monitoring of vitamin K antagonist therapy: comparative performance of point-of-care and laboratory-derived testing.
Bonar R; Mohammed S; Favaloro EJ
Semin Thromb Hemost; 2015 Apr; 41(3):279-86. PubMed ID: 25839866
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial.
Paikin JS; Manolakos JJ; Eikelboom JW
Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):965-72. PubMed ID: 23030284
[TBL] [Abstract][Full Text] [Related]
17. [Rivaroxaban in prevention of stroke in patients with atrial fibrillation].
Simonyi G; Medvegy M
Ideggyogy Sz; 2012 Nov; 65(11-12):365-8. PubMed ID: 23289170
[TBL] [Abstract][Full Text] [Related]
18. Performance of a point-of-care device in determining prothrombin time in supra-therapeutic INRs.
Hashimoto VA; De Paula EV; Colella MP; Luz Fiusa MM; Montalvao SA; Machado TF; Orsi FA; Annichino-Bizzacchi JM
Int J Lab Hematol; 2013 Apr; 35(2):211-6. PubMed ID: 23173728
[TBL] [Abstract][Full Text] [Related]
19. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of point of care coagulometers compared to reference laboratory measurements in patients on oral anticoagulation therapy.
Dillinger JG; Si Moussi T; Berge N; Bal Dit Sollier C; Henry P; Drouet L
Thromb Res; 2016 Apr; 140():66-72. PubMed ID: 26901852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
